Global & Disaster Medicine» Blog Archive » SIGA Technologies, Inc. announces the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral formulation of TPOXX® (tecovirimat) to treat smallpox.

SIGA Technologies, Inc. announces the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral formulation of TPOXX® (tecovirimat) to treat smallpox.

December 13th, 2017

“…..If approved, the oral drug would be the first FDA-approved treatment for smallpox, a disease that has been eradicated but could be used as a bioterror weapon. The news comes on the heels of media reports that North Korea could be building a bioweapons program that might include smallpox.….”

This entry was posted on Wednesday, December 13th, 2017 at 2:35 am and is filed under Smallpox .
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Global & Disaster Medicine

SIGA Technologies, Inc. announces the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral formulation of TPOXX® (tecovirimat) to treat smallpox.

Categories

Recent Posts

Archives

Admin